$CSTL News
Last published 1d ago
- 1d agoCSTLCastle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First CulturePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...
- 1d agoCSTLCastle Biosciences to Present at the Piper Sandler 38th Annual Healthcare ConferencePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 2d agoCSTLDecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC StagingPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will...
- 1w agoCSTLCastle Biosciences Q3 2026 Earnings Call - CASTLE BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, and welcome to CASEL Bioscience third quarter 2026 conference call. As a reminder, today's call is being recorded. We will begin today's called with opening remarks and introductions, followed by a questi
- 1w agoCSTLCASTLE BIOSCIENCES INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoCSTLCastle Biosciences to Participate in Upcoming Investor ConferencesPR NewswireFRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is
- 4w agoCSTLCastle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026PR NewswireFRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial
- 1mo agoCSTLACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusPR NewswireStudies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences,
- 1mo agoCSTLLate-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical ManagementPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on...
- 1mo agoCSTLNew Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's EsophagusPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...
- 1mo agoCSTLNew Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™PR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...
- 1mo agoCSTLCastle Biosciences to Open New Laboratory Facility in ScottsdalePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of...
- 1mo agoCSTLNew Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's EsophagusPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...
- 2mo agoCSTLJAAD Publication Shows Improved Performance of DecisionDx®-SCCPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...
- 2mo agoCSTLSciBase receives additional order from Castle Biosciences, advancing the collaborationPR NewswireSciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has...
- 2mo agoCSTLSciBase receives additional order from Castle Biosciences, advancing the collaborationPR NewswireSciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has...
- 2mo agoCSTLCastle Biosciences to Participate in Upcoming Investor ConferencesPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 2mo agoCSTLCastle Biosciences Approved for Dual Listing on Nasdaq TexasPR NewswireFRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have
- 3mo agoCSTLCG 46TH ANNUAL GROWTH CONFERENCE - CASTLE BIOSCIENCES INCEarnings Call TranscriptsHi, welcome to the Cancord World Conference. I'm Tom Neeson, I'm a doctoral scientist with Diagnostics at Cancорд. Please welcome to your first live chat with Castle Biosciences. Castle offers a range of tests across ger
- 3mo agoCSTLCastle Biosciences Q2 2026 Earnings Call - CASTLE BIOSCIENCES INCEarnings Call TranscriptsGood afternoon, and welcome to the CASEL Biosciences Second Quarter 2026 Conference Call. As a reminder, today's call is being recorded. We will begin today's calls with opening remarks and introductions, followed by a q
- 3mo agoCSTLCastle Biosciences Reports Second Quarter 2026 ResultsPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial...
- 3mo agoCSTLCastle Biosciences to Present at the Canaccord Genuity 46th Annual Growth ConferencePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 4mo agoCSTLCastle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ TestPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...
- 4mo agoCSTLCastle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026PR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...
- 4mo agoCSTLDecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node BiopsyPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication ...
- 4mo agoCSTLCastle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business JournalPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank...
- 4mo agoCSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June...
- 5mo agoCSTLCastle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's EsophagusPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 5mo agoCSTLJefferies Global Healthcare Conference in New York - CASTLE BIOSCIENCES INCEarnings Call TranscriptsGood afternoon and welcome to the Jefferies Global Healthcare Conference. My name is Lucy Laster from the Healthcare Investment Banking Team, and I'm here today with Frank Metzold and CEO, sorry, Derek Metzhold, CEO, and
- 6mo agoCSTLCastle Biosciences to Present at the 2026 Jefferies Global Healthcare ConferencePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 6mo agoCSTLCastle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics InnovationPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 6mo agoCSTLCastle Biosciences Reports First Quarter 2026 ResultsPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial...
- 6mo agoCSTLCastle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness MonthPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its...
- 6mo agoCSTLNew Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's EsophagusPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data...
- 6mo agoCSTLCastle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMSPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present ...
- 7mo agoCSTLCastle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026PR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...
- 7mo agoCSTLCastle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive YearPR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...
- 7mo agoCSTLCastle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026PR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the...
- 8mo agoCSTLProspective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNBGlobeNewswireAmong all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by
- 8mo agoCSTLDecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% RiskGlobeNewswireStudy results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the
- 8mo agoCSTLCastle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNBGlobeNewswireFRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating
- 8mo agoCSTLCastle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, TexasGlobeNewswireFRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand
- 8mo agoCSTLCastle Biosciences Reports Fourth Quarter and Full–Year 2025 ResultsGlobeNewswire2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast
- 8mo agoCSTLProspective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic DermatitisGlobeNewswireFRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a
- 9mo agoCSTLCastle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026GlobeNewswireFRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its
- 10mo agoCSTLCastle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 ResultsGlobeNewswire2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased
- 10mo agoCSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the
- 11mo agoCSTLLandmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal MelanomaGlobeNewswireFRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest
- 11mo agoCSTLSystematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal CancerGlobeNewswireFRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new
- 11mo agoCSTLExpert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with MelanomaGlobeNewswireFRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an